Q. Anstee

Epidemiology · 2006–2024

A researcher in the Science corpus: 20 papers; trusts 7 researchers and is trusted by 7 researchers here, as inferred from the citation graph.

Subfields

• Epidemiology — 350 citations into it; #605 of 2,148 by trust here, #197 by citations
• Hepatology — 211 citations into it
• Endocrinology, Diabetes and Metabolism — 196 citations into it; #235 of 623 by trust here, #102 by citations
• Pathology and Forensic Medicine — 56 citations into it; #385 of 414 by trust here, #163 by citations
• Genetics — 20 citations into it

Whom Q. Anstee trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. A. Sanyal
2. Herbert Tilg
3. Z. Younossi
4. S. Friedman
5. V. Ratziu
6. J. Browning
7. L. Adams
8. G. Targher
9. D. Kleiner
10. G. Fantuzzi

Who trusts Q. Anstee overall

1. G. Targher
2. A. Lonardo
3. Megan H. Bair-Merritt
4. Z. Younossi
5. Christopher D. Byrne
6. S. Friedman

Papers from Q. Anstee's perspective

Ordered by how strongly the researchers Q. Anstee trusts endorse each paper. Same corpus, a different order for every researcher.

1. ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (Hepatology)
2. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. (Gastroenterology)
3. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome (Hepatology)
4. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (Obesity Facts)
5. Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases
6. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The… (Journal of the American College of Cardiology)
7. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (Hepatology)
8. Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy (Annals of Internal Medicine)
9. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (Nature Reviews Gastroenterology &Hepatology)
10. Molecular mediators of hepatic steatosis and liver injury. (Journal of Clinical Investigation)

Their papers

• Cellular senescence drives age-dependent hepatic steatosis (2017) — 924 citations
• A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. (2024) — 1,246 citations
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
• Advancing the global public health agenda for NAFLD: a consensus statement (2021) — 631 citations
• NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) — 1,066 citations
• A new definition for metabolic associated fatty liver disease: an international expert consensus statement. (2020) — 3,051 citations
• FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study (2020) — 638 citations
• Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. (2020) — 864 citations
• Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. (2019) — 1,205 citations
• Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
• From NASH to HCC: current concepts and future challenges (2019) — 1,223 citations
• Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) — 1,677 citations
• Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases (2017) — 1,030 citations
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016) — 918 citations
• Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) — 799 citations
• Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015) — 1,003 citations
• TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) — 596 citations
• Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (2013) — 1,661 citations
• Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research (2006) — 750 citations